Hanall Biopharma Working Capital to Net Assets Ratio
Hanall Biopharma working capital to net assets ratio. Hanall Biopharma (009420) has a Working Capital to Net Assets ratio of 24.0% as of September 2025. Working capital of ₩37.81 Billion (current assets of ₩75.34 Billion minus current liabilities of ₩37.53 Billion) is measured against net assets of ₩157.65 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Hanall Biopharma (2013–2024)
Working capital to net assets ratio of Hanall Biopharma from 2013 to 2024. This chart shows how Hanall Biopharma's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2013 to 2024. As of September 2025, the ratio stands at 24.0%, reflecting working capital of ₩37.81 Billion against net assets of ₩157.65 Billion KRW. Explore Hanall Biopharma (009420) investment intensity to see how much of total assets are deployed in long-term investments.
Hanall Biopharma Working Capital to Net Assets Ratio by Year (2013–2024)
Hanall Biopharma working capital to net assets ratio by year from 2013 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Hanall Biopharma from 2013 to 2024, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 009420 asset base.
| Year | WC/NA Ratio | Working Capital (KRW) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 30.1% | ₩50.63 Billion | ₩168.35 Billion | ₩85.35 Billion | ₩34.72 Billion | ▼ -10.7 pp |
| 2023 | 40.8% | ₩75.93 Billion | ₩186.22 Billion | ₩113.58 Billion | ₩37.65 Billion | ▼ -8.7 pp |
| 2022 | 49.5% | ₩83.25 Billion | ₩168.26 Billion | ₩111.79 Billion | ₩28.53 Billion | ▼ -9.7 pp |
| 2021 | 59.1% | ₩96.69 Billion | ₩163.49 Billion | ₩118.81 Billion | ₩22.12 Billion | ▲ +0.5 pp |
| 2020 | 58.6% | ₩106.30 Billion | ₩181.27 Billion | ₩129.36 Billion | ₩23.07 Billion | ▼ -17.5 pp |
| 2019 | 76.1% | ₩106.91 Billion | ₩140.42 Billion | ₩134.30 Billion | ₩27.38 Billion | ▼ -15.0 pp |
| 2018 | 91.2% | ₩106.60 Billion | ₩116.92 Billion | ₩128.41 Billion | ₩21.81 Billion | ▲ +14.2 pp |
| 2017 | 77.0% | ₩85.58 Billion | ₩111.20 Billion | ₩138.37 Billion | ₩52.79 Billion | ▼ -1.7 pp |
| 2016 | 78.6% | ₩82.04 Billion | ₩104.36 Billion | ₩96.44 Billion | ₩14.39 Billion | ▼ -4.0 pp |
| 2015 | 82.6% | ₩78.69 Billion | ₩95.22 Billion | ₩92.77 Billion | ₩14.08 Billion | ▲ +16.9 pp |
| 2014 | 65.7% | ₩30.11 Billion | ₩45.81 Billion | ₩63.30 Billion | ₩33.19 Billion | ▲ +18.1 pp |
| 2013 | 47.6% | ₩28.37 Billion | ₩59.63 Billion | ₩61.31 Billion | ₩32.95 Billion | — |